Nuvectis Pharma (NVCT) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
21 Aug, 2026Company overview and business model
Focuses on developing precision medicines for oncology addressing unmet medical needs.
Pipeline includes NXP100 (Factor B inhibitor), NXP200 (BRAF inhibitor), and NXP900 (SRC/YES1 kinase inhibitor), all in advanced or clinical stages.
Holds exclusive worldwide rights (excluding China) for NXP100 and NXP200, and global rights for NXP900.
Incorporated in Delaware in 2020, rebranded in 2021, and headquartered in Fort Lee, NJ.
Financial performance and metrics
As of July 31, 2026, 32,614,066 shares of common stock were outstanding.
Historical net tangible book value as of June 30, 2026, was $0.34 per share; pro forma as adjusted after recent offerings would be $5.29 per share.
Immediate dilution to new investors in the ATM offering is estimated at $18.06 per share.
Use of proceeds and capital allocation
Proceeds will fund advancement of NXP100, NXP200, NXP900, hiring, capital expenditures, public company costs, and general corporate purposes.
May allocate funds to acquisitions or investments in complementary businesses, products, or technologies.
Management retains broad discretion over use of proceeds.
Latest events from Nuvectis Pharma
- Advancing late-stage precision therapies for complement diseases and cancer with strong clinical data.NVCT
Corporate presentation - Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCTQ2 2026
- Late-stage NXP100 and NXP200 in-licensed, expanding pipeline in complement and oncology.NVCTStatus update
- Director election and auditor ratification approved; full results to be filed with SEC.NVCTAGM 2026
- NXP900 demonstrates potent, selective SRC inhibition and promising safety in early clinical trials.NVCTH.C. Wainwright 4th Annual BioConnect Investor Conference
- NXP900 shows promise in overcoming resistance in solid tumors and NSCLC with strong early data.NVCTCorporate presentation
- Q1 2026 net loss was $6.1M as NXP900 clinical progress drove higher R&D and G&A costs.NVCTQ1 2026
- Vote on director election and auditor ratification at the June 2026 annual meeting.NVCTProxy filing
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event